Hong Kong-based Immuno Cure BioTech has closed the US$12 million tranche of its US$27 million Series A fundraising round, led by Gobi Partners-managed AEF Greater Bay Area Fund.
The biotech company will use the capital to accelerate the development of DNA vaccines and antibodies besides preparing for an IPO in Hong Kong.
Immuno Cure focuses on R&D of immunotherapies for cancers, inflammatory and infectious diseases based on its patented “PD-1-enhanced DNA Vaccine Platform” and “Anti-Δ42PD1 Antibody Platform” with two DNA vaccine candidates, ICVAX and ICCOV, currently in clinical trials.
Also Read: Mirxes lands US$50M to take its cancer early detection solutions to new markets
ICVAX, a therapeutic DNA vaccine candidate against HIV/AIDS, was developed with the aim of inducing broadly reactive polyfunctional viral-specific T cells to achieve a functional cure for HIV/AIDS. The Phase-I clinical trial of ICVAX, which is underway in Shenzhen, is designed as a randomised, double-blinded, placebo-controlled study to evaluate the safety and immunogenicity of ICVAX in a total of 45 stable HIV/AIDS patient volunteers under antiretroviral therapy.
ICCOV, a preventive COVID-19 DNA vaccine candidate, has entered the Phase IIa clinical trial in Hong Kong, which is designed as an open-label study to evaluate the immunogenicity and safety of ICCOV as a booster vaccine in a total of 60 healthy adult volunteers between 18 and 75 years of age.
Also Read: How is AI transforming the future of cancer diagnosis
Dr Xia JIN, CEO of Immuno Cure, said: “Immuno Cure will continue to be at the frontier of DNA medicines, antibodies and innovative immunotherapies, conducting R&D on novel and effective vaccine technologies to enhance our arsenal against cancers and infectious diseases.”
—
The post Immuno Cure bags US$12M Series A funding, gears up for Hong Kong IPO appeared first on e27.